Neogenomics (NEO) Liabilities and Shareholders Equity (2010 - 2026)

Neogenomics (NEO) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.3 billion, down 15.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.5 billion (down 16.08% YoY), and the FY2025 annual result was $1.4 billion, down 16.98% from the prior year.
• Liabilities and Shareholders Equity was $1.3 billion for Q1 2026 at Neogenomics, down from $1.4 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q1 2022 and troughed at $1.3 billion in Q1 2026.
• Average Liabilities and Shareholders Equity over 5 years is $1.6 billion, with a median of $1.6 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity increased 22.43% in 2022 and fell 16.98% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then fell by 3.38% to $1.7 billion in 2023, then decreased by 2.57% to $1.6 billion in 2024, then dropped by 16.98% to $1.4 billion in 2025, then slipped by 0.98% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.